Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability

Jill Clayton-Smith, Rebecca Bromley, John Dean, Hubert Journel, Sylvie Odent, Amanda Wood, Janet Williams, Verna Cuthbert, Latha Hackett, Neelo Aslam, Heli Malm, Gregory James, Lena Westbom, Ruth Day, Edmund Ladusans, Adam Jackson, Iain Bruce, Robert Walker, Sangeet Sidhu, Catrina Dyer & 5 muut Jane Ashworth, Daniel Hindley, Gemma Arca Diaz, Myfanwy Rawson, Peter Turnpenny

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature.
Alkuperäiskielienglanti
LehtiOrphanet journal of rare diseases
Vuosikerta14
Numero1
ISSN1750-1172
DOI - pysyväislinkit
TilaJulkaistu - 19 heinäkuuta 2019
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3121 Sisätaudit

Lainaa tätä

Clayton-Smith, Jill ; Bromley, Rebecca ; Dean, John ; Journel, Hubert ; Odent, Sylvie ; Wood, Amanda ; Williams, Janet ; Cuthbert, Verna ; Hackett, Latha ; Aslam, Neelo ; Malm, Heli ; James, Gregory ; Westbom, Lena ; Day, Ruth ; Ladusans, Edmund ; Jackson, Adam ; Bruce, Iain ; Walker, Robert ; Sidhu, Sangeet ; Dyer, Catrina ; Ashworth, Jane ; Hindley, Daniel ; Diaz, Gemma Arca ; Rawson, Myfanwy ; Turnpenny, Peter. / Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Julkaisussa: Orphanet journal of rare diseases. 2019 ; Vuosikerta 14, Nro 1.
@article{1293cde498454a15a31b37480e505ecd,
title = "Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability",
abstract = "A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature.",
keywords = "3121 Internal medicine",
author = "Jill Clayton-Smith and Rebecca Bromley and John Dean and Hubert Journel and Sylvie Odent and Amanda Wood and Janet Williams and Verna Cuthbert and Latha Hackett and Neelo Aslam and Heli Malm and Gregory James and Lena Westbom and Ruth Day and Edmund Ladusans and Adam Jackson and Iain Bruce and Robert Walker and Sangeet Sidhu and Catrina Dyer and Jane Ashworth and Daniel Hindley and Diaz, {Gemma Arca} and Myfanwy Rawson and Peter Turnpenny",
year = "2019",
month = "7",
day = "19",
doi = "10.1186/s13023-019-1064-y",
language = "English",
volume = "14",
journal = "Orphanet journal of rare diseases",
issn = "1750-1172",
publisher = "BMC",
number = "1",

}

Clayton-Smith, J, Bromley, R, Dean, J, Journel, H, Odent, S, Wood, A, Williams, J, Cuthbert, V, Hackett, L, Aslam, N, Malm, H, James, G, Westbom, L, Day, R, Ladusans, E, Jackson, A, Bruce, I, Walker, R, Sidhu, S, Dyer, C, Ashworth, J, Hindley, D, Diaz, GA, Rawson, M & Turnpenny, P 2019, 'Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability', Orphanet journal of rare diseases, Vuosikerta 14, Nro 1. https://doi.org/10.1186/s13023-019-1064-y

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. / Clayton-Smith, Jill; Bromley, Rebecca; Dean, John; Journel, Hubert; Odent, Sylvie; Wood, Amanda; Williams, Janet; Cuthbert, Verna; Hackett, Latha; Aslam, Neelo; Malm, Heli; James, Gregory; Westbom, Lena; Day, Ruth; Ladusans, Edmund; Jackson, Adam; Bruce, Iain; Walker, Robert; Sidhu, Sangeet; Dyer, Catrina; Ashworth, Jane; Hindley, Daniel; Diaz, Gemma Arca; Rawson, Myfanwy; Turnpenny, Peter.

julkaisussa: Orphanet journal of rare diseases, Vuosikerta 14, Nro 1, 19.07.2019.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability

AU - Clayton-Smith, Jill

AU - Bromley, Rebecca

AU - Dean, John

AU - Journel, Hubert

AU - Odent, Sylvie

AU - Wood, Amanda

AU - Williams, Janet

AU - Cuthbert, Verna

AU - Hackett, Latha

AU - Aslam, Neelo

AU - Malm, Heli

AU - James, Gregory

AU - Westbom, Lena

AU - Day, Ruth

AU - Ladusans, Edmund

AU - Jackson, Adam

AU - Bruce, Iain

AU - Walker, Robert

AU - Sidhu, Sangeet

AU - Dyer, Catrina

AU - Ashworth, Jane

AU - Hindley, Daniel

AU - Diaz, Gemma Arca

AU - Rawson, Myfanwy

AU - Turnpenny, Peter

PY - 2019/7/19

Y1 - 2019/7/19

N2 - A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature.

AB - A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but these are now acknowledged following the publication of the outcomes of several prospective studies and registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern of major malformations and significant intellectual disability to the other end of the continuum, characterised by facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary care but information regarding management is currently lacking in the medical literature.

KW - 3121 Internal medicine

U2 - 10.1186/s13023-019-1064-y

DO - 10.1186/s13023-019-1064-y

M3 - Article

VL - 14

JO - Orphanet journal of rare diseases

JF - Orphanet journal of rare diseases

SN - 1750-1172

IS - 1

ER -